Semaglutide (GLP-1 Receptor Agonist)
Treatment for Diabetes Mellitus Type 2
Typical Dosage: Oral: 3-14 mg daily; Injectable: 0.25-2 mg weekly
Effectiveness
90%
Safety Score
60%
Clinical Trials
27
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Oral: 3-14 mg daily; Injectable: 0.25-2 mg weekly
Time to Effect
2-4 weeks for glucose, 2-3 months for full effect
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
1000(Treat 1000 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$13,000
Monitoring:$450
Side Effect Mgmt:$100
Total Annual:$13,550
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$80,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$17,371.79
Cost per Remission
$135,500
Comparison vs Sitagliptin
Cost Difference
+$8,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Semaglutide (GLP-1 Receptor Agonist) Outcomes
for Diabetes Mellitus Type 2
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+78%
Remission Rate
+10%
Common Side Effects
Nausea
+30%
Vomiting
+10%
Diarrhea
+15%
Constipation
+10%
Pancreatitis
+0.1%
Active Clinical Trials
10 active trials recruiting for Semaglutide (GLP-1 Receptor Agonist) in Diabetes Mellitus Type 2
Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes
NCT07558863RECRUITINGPHASE4
60 participants
INTERVENTIONAL
Nanjing, China
Started: Apr 1, 2026
Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
NCT07428746RECRUITINGPHASE3
20 participants
INTERVENTIONAL
Atlanta, United States
Started: May 7, 2026
Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes
NCT06715514ACTIVE NOT RECRUITINGNA
96 participants
INTERVENTIONAL
Bern, Switzerland
Started: Feb 18, 2025
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
NCT05390892RECRUITINGPHASE4
6K participants
INTERVENTIONAL
Huntsville, United States +35 more
Started: Sep 26, 2022
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
NCT07325435ACTIVE NOT RECRUITINGPHASE4
60 participants
INTERVENTIONAL
Brooklyn, United States
Started: Dec 21, 2024
Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy
NCT07728669RECRUITINGNA
120 participants
INTERVENTIONAL
Almaty, Kazakhstan
Started: Jul 20, 2026
Gastric Emptying in Healthy Volunteers and GLP-1 Agonist Users
NCT06987669NOT YET RECRUITING
155 participants
OBSERVATIONAL
Started: May 17, 2025
Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 Diabetes
NCT07599046NOT YET RECRUITINGNA
20 participants
INTERVENTIONAL
Shenzhen, China
Started: Apr 30, 2026
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
NCT07628985NOT YET RECRUITINGPHASE3
374 participants
INTERVENTIONAL
Mexico City, Mexico +6 more
Started: Sep 1, 2026
Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
NCT07272837RECRUITING
50 participants
OBSERVATIONAL
Edmonton, Canada
Started: May 15, 2026
Completed Clinical Trials
6 completed trials for Semaglutide (GLP-1 Receptor Agonist) in Diabetes Mellitus Type 2
SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.
NCT05136287COMPLETED
140 participants
OBSERVATIONAL
Culleredo, Spain +10 more
Started: Feb 1, 2022
Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes
NCT06120556COMPLETED
130 participants
OBSERVATIONAL
Bari, Italy
Started: Jun 10, 2023
GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation
NCT07677865COMPLETED
214K participants
OBSERVATIONAL
Chengdu, China
Started: Jan 1, 2007
Adiponectin in Patients With Metabolic Disorders
NCT07539584COMPLETEDNA
130 participants
INTERVENTIONAL
Moscow, Russia
Started: Mar 1, 2022
Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial
NCT07732218COMPLETEDPHASE4
95 participants
INTERVENTIONAL
Peshawar, Pakistan
Started: Jul 4, 2022
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
NCT03987919COMPLETEDPHASE3
1.88K participants
INTERVENTIONAL
Birmingham, United States +126 more
Started: Jul 30, 2019
Showing 20 of 44 total trials